On 6 September 2021, following an invitation by Emer Cooke, executive director of the European Medicines Agency (EMA), a video conference took place between the EMA and Prescrire to discuss access to Agency documents.
This virtual meeting followed two exchanges of correspondence (in December 2020 and June 2021) concerning the EMA's slow response to requests for access to documents necessary for Prescrire's work, particularly drug packaging mock-ups.
During its contribution, Prescrire highlighted three problem areas:
- unacceptable delays in processing of requests for access to documents, caused mainly by the queuing system;
- censorship, i.e. redaction, of some, mainly clinical, data in Agency documents;
- revealing Prescrire's identity to the market authorisation holder concerned.
Prescrire also suggested some ways forward, and will continue to objectively assess progress in the Agency's transparency based on its requests for documents.
©Prescrire 1 July 2022
Source: "Access to EMA documents" Prescrire International 2022; 31 (239): 194. Subscribers only.
Enjoy full access to Prescrire International, and support independent information
|